41 episodes

Interviews and highlights from the 2016 ASH meeting.

ASH 2016 ecancer

    • Medicine

Interviews and highlights from the 2016 ASH meeting.

    • video
    Large granular lymphocyte proliferations in MDS

    Large granular lymphocyte proliferations in MDS

    Dr Roe speaks with ecancertv at ASH 2016 about genotyping and treatment outcomes for patients with myelodysplastic syndrome with T cell large granular lymphocyte proliferations (LGL).

    She describes characterisation of patients by age and risk, with a greater response to lenalidomide from patients without LGL clonal types.

    • 2 min
    • video
    Pacritinib versus best available therapy for low platelet Myelofibrosis

    Pacritinib versus best available therapy for low platelet Myelofibrosis

    Dr Mascarenhas speaks with ecancertv at ASH 2016 about pacritinib, an oral kinase inhibitor against JAK2, FLT3, IRAK1, and CSF1R.

    He describes the patient response to pacritinib, with a direct comparison to ruxolitinib (a JAK1/2 inhibitor) being of significant interest, and weighs measuring spleen volume reduction against other endpoints.

    Pacritinib is currently on full clinical hold by the FDA following deaths and cardiac events in PERSIST-1, which Dr Mascarenhas considers against the toxicity profile in this trial.

    • 3 min
    • video
    A new spin on leukaemia therapy

    A new spin on leukaemia therapy

    Prof Keating speaks with ecancertv at ASH 2016 about presentations from Dr Terry Fry and Dr Jeff Lancet, in which twists on existing leukaemia therapies gave new insight on disease treatment

    • 4 min
    • video
    Updates from the EURO-SKI trial of tyrosine kinase cessation

    Updates from the EURO-SKI trial of tyrosine kinase cessation

    Dr Mahon presents data at ASH 2016 with an update from the EURO-SKI trial of TKI cessation for myeloid leukaemia patients.

    • 6 min
    • video
    Vadastuximab talirine in combination for newly diagnosed AML

    Vadastuximab talirine in combination for newly diagnosed AML

    Prof Erba presents results at ASH 2016 from a phase 1b study of vadastuximab talirine, or 33A, administered alongside standard induction therapy for acute myeloid leukaemia.

    • 11 min
    • video
    TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial

    TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial

    Dr Mahon presents data at ASH 2016 with an update from the EURO-SKI trial of TKI cessation for myeloid leukaemia patients.

    • 2 min

Top Podcasts In Medicine

More by ecancer